Duality Biotherapeutics, Inc. (FRA:4ZB)

Market Cap	1.96B -41.8%
Revenue (ttm)	225.48M -4.6%
Net Income	-315.97M
EPS	-4.85
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	21.40
Previous Close	21.60
Day's Range	21.40 - 21.40
52-Week Range	18.60 - 58.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carci...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2019
• Employees: 231
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4ZB

Financial Performance

In 2025, Duality Biotherapeutics's revenue was 1.85 billion, a decrease of -4.61% compared to the previous year's 1.94 billion. Losses were -2.59 billion, 147.0% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error